GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK plc has announced provisional dividend dates for the year 2026, outlining key ...

GSK’s antibody-drug conjugate strategy may be making more headlines recently, but the British pharma hasn’t forgotten about ...

GSK presents data from its advancing liver pipeline at AASLD 2025: London, UK Monday, November 10, 2025, 11:00 Hrs [IST] GSK plc will showcase latest advances in its liver pipelin ...

The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

GSK once dreamed of harnessing the CD226 axis to create a new generation of blockbuster cancer drugs. | GSK once dreamed of ...

Wondering if GSK is actually undervalued or if there's more to the story than recent headlines suggest? You're not alone, and we're about to dive into what those numbers really mean. Despite a slight ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the ...

Emma Walmsley and her GSK CEO successor, Luke Miels, are safeguarding the British pharma’s 40-billion-pound sales projection ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.

GSK Pharma share price fell 3 per cent after it reported a lower-than-expected top-line for the second quarter of the current ...

As China's healthcare and policy environment continues to improve, global pharmaceutical company GlaxoSmithKline (GSK) is ...